LDLRAD4

Across TCGA pan-cancer cohorts, LDLRAD4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LDLRAD4 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher LDLRAD4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LDLRAD4 expression acts as an unfavorable survival marker.

STAD, UCEC, and LUSC are the cancer types where LDLRAD4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	III,IV	0.093	0.636	<.001	18	view →
UCEC	OS	Median	IV	0.282	0.604	.024	12	view →
LUSC	OS	Median	All	0.011	0.819	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	DFS	Median	II,III,IV	0.083	0.427	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LDLRAD4–STAD (OS)

Open the STAD breakdown →